Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > New Questions
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2261)
•••
Comment by Boomskidon Jun 09, 2023 3:19pm
115 Views
Post# 35489058

RE:RE:RE:RE:New Questions

RE:RE:RE:RE:New QuestionsI expect that's true, poof. I wasn't at the AGM. But my post wasn't about J&J.

What about the deals with Ellipses and Prothena? What part is Protalix playing in the Chiesi deal? Should Rathjen have tried to do the Midatech deal without disclosing that stuff to shareholders?

Were the Midatech/LT players made aware of these things that Bioasis shareholders were not made aware of? Did Midatech pump xB3 because they were also told things that Bioasis shareholders were not aware of? 

Would Bioasis be viable with any of those possible deals? Should they have been kept secret while at the same time xB3 was being denigrated and devalued by Bioasis?

Are you avoiding the questions because you can't answer them or because the answers don't support your agenda?

The poster, DaTruth1234 (DT) thinks that you're very smart, poof, given your, whatever it is you're given. 

No copy/pasting. What was Dr. Deborah Rathjen's agenda, poof? And please, don't post another laffer. You don't want to disappoint DT. He thinks very highly of you.

jd
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities